Immuno-PET Imaging of CD69 Visualizes T-Cell Activation and Predicts Survival Following Immunotherapy in Murine Glioblastoma.
Michal NisnboymSarah R VinczeZujian XiongChaim T SneidermanRebecca A RaphaelBo LiAmbika P JaswalReidAnn E SeverKathryn E DayJoseph D LaTocheLesley M FoleyHanieh KarimiT Kevin HitchensSameer AgnihotriBaoli HuDhivyaa RajasundaramCarolyn J AndersonDeborah T BlumenthalThomas M PearceShikhar UttamJessie R NedrowAshok PanigrahyIan F PollackFrank Scott LiebermanJan DrappatzItay RaphaelWilson B EdwardsGary KohanbashPublished in: Cancer research communications (2023)
Immunotherapy may hold promise for the treatment of some patients with GBM. There is a need to assess therapy responsiveness to allow the continuation of effective treatment in responders and to avoid ineffective treatment with potential adverse effects in the nonresponders. We demonstrate that noninvasive PET/CT imaging of CD69 may allow early detection of immunotherapy responsiveness in patients with GBM.